- Poster presentation
- Open Access
Interleukin 1 blockade with canacinumab for hyperimmunoglobulin D and periodic fever syndrome
Pediatric Rheumatology volume 12, Article number: P270 (2014)
Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS; MIM# 260920) is a rare autosomal recessive autoinflammatory condition caused by mutations in the MVK gene, which encodes for mevalonate kinase. There is no standard treatment for HIDS.
We report on a 2 year-old Austrian boy with recurrent episodes of fever, febrile seizures, arthralgias, and splenomegaly. Rash and abdominal pain were also seen occasionally. During attacks an acute-phase response was detected. Clinical and laboratory improvement was seen between attacks. These findings led to the tentative diagnosis of HIDS.
Sequencing of the MVK gene showed a homozygous c.1129G>A (p.Val377Ile, also known as V377I) mutation in the child, while the healthy non-consanguineous parents were heterozygous. The mutation is known to be associated with HIDS.
Therapy with nonsteroidal anti-inflammatory drugs during attacks had poor benefit. A further febrile episode resulted in a status epilepticus. Treatment with canakinumab was initiated and a final dose of 4 mg/kg every 4 weeks resulted in the disappearance of febrile attacks and a considerable improvement of patient´s quality of life during a 6-month follow-up period. The drug has been well tolerated, and no side effects were observed.
Treatment with canakinumab is a therapeutical option for patients with HIDS.
Disclosure of interest
About this article
Cite this article
Brunner, J., Binder, E., Karall, D. et al. Interleukin 1 blockade with canacinumab for hyperimmunoglobulin D and periodic fever syndrome. Pediatr Rheumatol 12, P270 (2014). https://doi.org/10.1186/1546-0096-12-S1-P270
- Status Epilepticus
- Considerable Improvement
- Recurrent Episode
- Febrile Seizure
- Final Dose